Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

We noticed this today when the trades showed up on publicly available options history that we track ... spotted 10 uncommon options trades for Vertex Pharmaceuticals. This isn't normal.

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock’s 50 day simple moving average is $464.06 and its 200-day simple moving average is $462.31.

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.